Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) EV/FCF
As of 9 October 2026, Eli Lilly and Company (LLY) trades at a EV/FCF of 53.9×. Over the past ten years it has ranged from 16.2× (February 2018) to 534× (June 2024); the current reading is higher than 70% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 89.5× | (26.10%) |
| FY2024 | 121× | (45.88%) |
| FY2023 | 224× | 277.89% |
| FY2022 | 59.2× | 45.26% |
| FY2021 | 40.8× | 35.42% |
| FY2020 | 30.1× | (6.35%) |
| FY2019 | 32.1× | 25.74% |
| FY2018 | 25.6× | 38.98% |
| FY2017 | 18.4× | (2.79%) |
| FY2016 | 18.9× | (51.17%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 54.7× | (10.57%) |
| Mar 2026 | 61.2× | (31.58%) |
| Dec 2025 | 89.5× | 42.35% |
| Sep 2025 | 62.8× | (39.52%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| MRK Merck & Co., Inc. compare | 25.1× |
| AMGN Amgen Inc. compare | 27.4× |
| JNJ Johnson & Johnson compare | 28.4× |
| ABBV AbbVie Inc. compare | 30.4× |
| AZN AstraZeneca PLC compare | 43.3× |
| LLY Eli Lilly and Company | 53.9× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement